Corvus Pharmaceuticals (CRVS) Capital Expenditures Growth (3y) (2018 - 2026)
Corvus Pharmaceuticals (CRVS) Capital Expenditures Growth (3y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -12.25% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Corvus Pharmaceuticals | 1.23 Bn | 1.23 Bn | - | 38.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.84% |
| Dec 31, 2025 | -57.34% |
| Sep 30, 2025 | 239.84% |
| Dec 31, 2024 | 85.46% |
| Sep 30, 2024 | -99.55% |
| Jun 30, 2024 | 27.78% |
| Mar 31, 2024 | -34.40% |
| Dec 31, 2022 | 104.61% |
| Sep 30, 2022 | 25.99% |
| Dec 31, 2021 | 32.76% |
| Sep 30, 2021 | 51.13% |
| Jun 30, 2021 | -99.22% |
| Mar 31, 2021 | 50.70% |
| Dec 31, 2020 | 12.28% |
| Sep 30, 2020 | 21.25% |
| Dec 31, 2019 | 26.79% |
| Sep 30, 2019 | -74.80% |
| Mar 31, 2019 | -70.12% |
| Dec 31, 2018 | 11.63% |
| Sep 30, 2018 | -33.28% |